Industry, regional funding and support organizations, the region’s university system and local and state government entities recognize this workforce challenge and have been collaborating to build the cell and gene therapy workforce infrastructure required to keep the personalized medicine workforce pipeline primed.
To discuss how the Biohealth Capital Region would fare out in a potential recession, and whether it can actually avoid one, the I-270 Innovation Labs brought together an outstanding group of regional experts from across key sectors connected to both industries.
REGENXBIO Inc. (Nasdaq: RGNX) today announced a program update from its ongoing clinical investigation of RGX-314 for the treatment of wet AMD, a leading cause of vision loss globally.
To improve healthcare, startup IndyGeneUS is building a more equitable genomic data repository
Maryland founder Yusuf Henriques wants to make genomic data more accessible with his new startup. By Michaela Althouse / STAFF
Join 30,000+ readers who receive daily email updates from Technical.ly
ADVERTISEMENT
About Crossbeam VIEW OPEN POSITIONS
TOP ARTICLES
1
Promotions shouldn’t be a reward
2
Q&A: EY senior partner Marc Andersen discusses DC investment trends
3
Meet the 17 fellows joining Venture for America’s 2022 cohort in Baltimore
Yusuf Henriques believes our understanding of genes and medicine is incomplete without more people of color and women in clinical research trials.
(Image by Flickr user National Human Genome Research Institute, used via a Creative Commons license)
In the early days of the COVID-19 pandemic, many people picked up an indoor hobby or two. For DC founder Yusuf Henriques, it was hackathons.
At the time, Henriques co-created a virtual hackathon on racism and healthcare from the Massachusetts Institute of Technology, which led him to look closer at a particular aspect of healthcare.
“We started looking at the structural racism that has been built into the system, lack of access, not enough women and minorities in clinical trials,” Henriques told Technical.ly….
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors. In addition, NextCure announced it has entered into a supply agreement for KEYTRUDA with Merck (known as MSD outside the United States and Canada).
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic foot osteomyelitis (DFO). APT is evaluating safety and efficacy of its precision phage-based therapy in the ongoing Phase 1/2 DANCE™ (DFO Adaptive Novel Care Evaluation) clinical trial.
The Maryland Stem Cell Research Commission announced it will grant $4,165,325 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland.
Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial
(Photo: Business Wire)
October 04, 2022 08:29 AM Eastern Daylight Time
GAITHERSBURG, Md–(BUSINESS WIRE)–Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic foot osteomyelitis (DFO). APT is evaluating safety and efficacy of its precision phage-based therapy in the ongoing Phase 1/2 DANCE™ (DFO Adaptive Novel Care Evaluation) clinical trial.
“We look forward to our continued support from the DHA, as well as presenting our initial clinical data from our ongoing Phase 1/2 DANCE trial in the second half of 2023.”
Tweet this
“We are pleased to announce this expansion of our existing DHA agreement supporting development of phage-based therapies, further highlighting DHA’s commitment to the potential of our adaptive therapeutic approach to improve treatment of a variety of antimicrobial-resistant bacterial infections. This additional $5 million supports our Phase 1/2 DANCE™ clinical trial which is progressing towards generating APT’s first clinical…
Baltimore company raises $19.4M to change the treatment of brain diseases Email Facebook LinkedIn Twitter Share article
Deborah Weidman is a co-founder of CraniUS, which recently raised $19.4 million.
Courtesy of Deborah Weidman
By Matt Hooke – Reporter
October 03, 2022, 08:10am EDT
A Baltimore medical device firm that aims to improve the treatment of brain diseases has raised $19.4 million, one of the larger funding rounds in the region so far this year.
Hampden-based CraniUS’ series A funding round was led entirely by private investors, such as family offices, with no participation from venture capital firms.
The $19.4 million will give the 17-person team the funds necessary to workshop and develop prototypes, as the company hopes to start in-person trials in 2024.
The round had 21 investors, U.S. Securities and Exchange Commission filings show. CEO Michael Maglin said the company did not pursue venture capital because it already had several board members in mind for the company and did not want to give up a large amount of equity in its first capital raise. The round closed at the end of April and began in Sept. 2021.
CraniUS is developing an implantable device that delivers medicine straight into the…
miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
by Ashwin Kulkarni | Oct 4, 2022 | New
Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD
miRecule will receive an upfront payment with potential future milestone payments of nearly $400 million, in addition to tiered royalties
Collaboration marks the first licensing transaction leveraging miRecule’s proprietary DREAmiRTM discovery platform, validating foundational science, and bolstering commitment to further expansion of the company’s RNA therapeutic pipeline
GAITHERSBURG, Maryland– October 4, 2022 – miRecule, Inc., an innovator of next-generation RNA therapeutics, today announced a strategic collaboration and exclusive license agreement with Sanofi to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The collaboration marks miRecule’s first licensing transaction leveraging its proprietary DREAmiR platform.
FSHD is the second most common type of muscular dystrophy – affecting more than one million individuals worldwide with no approved treatments. Patients with causative genetic mutations experience lifelong deterioration of muscle function and progressive disability. The collaboration will combine miRecule’s anti-DUX4 RNA therapy (discovered through…
